Bumetanide and Indapamide share 13 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.382 means 38% of the combined target set is bound by both compounds. The IDF-weighted score of 0.345 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Bumetanide and Indapamide have in common?
Bumetanide and Indapamide share 13 molecular targets with a Jaccard similarity of 38%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Bumetanide and Indapamide be combined?
Bumetanide and Indapamide share 13 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Bumetanide or Indapamide?
Both Bumetanide and Indapamide have substantial PubMed research. View their individual profiles for full evidence scores.